Loading...
XNAS
VCYT
Market cap4.73bUSD
Jul 09, Last price  
59.30USD
1D
5.67%
1Q
90.74%
Jan 2017
666.15%
IPO
378.61%
Name

Veracyte Inc

Chart & Performance

D1W1MN
XNAS:VCYT chart
P/E
71.31
P/S
9.15
EPS
0.83
Div Yield, %
—
Shrs. gr., 5y
8.64%
Rev. gr., 5y
34.50%
Revenues
517m
+16.01%
2,645,00011,628,00021,884,00038,190,00049,503,00065,085,00071,953,00092,008,000120,368,000117,483,000219,514,000296,536,000361,051,000445,764,000517,145,000
Net income
66m
+174.89%
-14,445,000-18,649,000-25,580,000-29,373,000-33,704,000-31,358,000-31,003,000-22,999,000-12,599,000-34,909,000-75,563,000-36,560,000-74,404,00024,138,00066,353,000
CFO
136m
+81.51%
-13,524,000-7,167,000-19,159,000-27,632,000-26,965,000-27,982,000-23,915,000-13,521,000-3,232,000-9,711,000-31,621,0007,535,00044,222,00075,096,000136,307,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
URL
https://www.veracyte.com/
IPO date
Oct 30, 2013
Employees
787
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT